7.1.1 In addition to the large number of candidate vaccines and therapeutics in the pipeline, the awarding of the 2023 Nobel Prize in Physiology or Medicine[91] to the initial developers of mRNA treatments underscores the importance that mRNA technology will play in the biopharma industry going forward. The mRNA market continues to demonstrate substantial growth potential across both therapeutic and vaccine applications. These projections are underpinned by increasing demand for more precise, rapid-response modalities and expanding pipelines in high-impact disease areas such as cancer, infectious diseases, and rare genetic disorders.
7.1.2 The global market for mRNA therapeutics is forecast to grow from $20.83 billion in 2025 to $42.64 billion by 2034, representing a compound annual growth rate (CAGR) of approximately 8.3%.[92] In the United States, where early clinical and regulatory infrastructure is particularly strong, the market is expected to grow from $5.48 billion to $11.89 billion over the same period, with a slightly higher CAGR of around 9%.[92]
7.1.3 This growth is driven by a surge in clinical development activity targeting a diverse array of disease areas. Oncology has emerged as a leading focus, particularly in the form of personalized cancer vaccines designed to elicit robust, patient-specific immune responses.[92][7] Rare diseases are another high-potential segment, with mRNA-based therapies being used to enable intracellular protein replacement where traditional enzyme or gene therapies fall short. In addition, multiple companies are pursuing mRNA therapies for genetic and neurological disorders, with recent deals and data releases underscoring growing investor confidence in this space.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
7.2.1 Although mRNA vaccines reached unprecedented commercial heights during the COVID-19 pandemic, the post-pandemic market remains resilient and primed for further growth. The global mRNA vaccine market is projected to increase from $10.4 billion in 2025 to $18 billion by 2030, at a CAGR of approximately 11.9%.[94]
7.2.2 New mRNA vaccine candidates are progressing in clinical trials for respiratory syncytial virus (RSV), influenza, cytomegalovirus (CMV), and HIV, signaling a shift toward seasonal and chronic infectious disease prevention. Furthermore, the platform’s inherent adaptability and rapid manufacturing turnaround continue to position it as a critical component of global pandemic preparedness strategies. The technology’s modularity enables swift redesign in response to emerging variants or entirely new pathogens, preserving its long-term strategic relevance even as immediate COVID-19 demand subsides.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
7.3.1 When considering the combined market for mRNA therapeutics and vaccines, the projected scale of growth is even more striking. Together, these segments are expected to expand from approximately $63 billion in 2025 to $253 billion by 2034, yielding a CAGR of 16.7%.[95] This explosive growth highlights the continuing maturation and diversification of the mRNA field and underscores its transition from an emergent modality to a foundational platform across multiple therapeutic categories.
7.3.2 While mRNA has garnered the most attention in recent years, it is part of a larger and increasingly diverse class of RNA-based therapeutics. This broader category includes RNA interference (RNAi), antisense oligonucleotides (ASOs), and other nucleic acid therapeutics, each with distinct mechanisms and development profiles. As the science matures, these modalities are finding applications across a widening range of diseases, fueling demand not only for therapeutic innovation but also for specialized manufacturing capabilities.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
7.4.1 The global market for RNA therapeutics overall is projected to grow from $12.4 billion in 2024 to $22.6 billion by 2034.[96] This figure encompasses multiple RNA-based technologies beyond mRNA, reflecting a more comprehensive picture of the nucleic acid therapeutic landscape.
7.4.2 RNAi, which operates by silencing specific gene transcripts, is expected to see rapid expansion in the coming decade. The RNAi therapeutics market is forecast to grow from $1.47 billion in 2025 to $5.1 billion by 2034, with significant activity in areas such as rare diseases, oncology, and cardiometabolic disorders.[97] Meanwhile, the market for nucleic acid therapeutics — including ASOs and other synthetic RNA-based agents — is projected to increase from $6.4 billion in 2025 to $17 billion by 2034, driven by technological advances and an expanding clinical pipeline.[92]
7.4.3 These modalities offer unique advantages in terms of targeting previously “undruggable” genes, tailoring treatments to specific patient populations, and avoiding permanent genomic edits. Together, they are helping to establish RNA-based mechanisms as a cornerstone of modern drug development.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
7.5.1 The accelerating growth of the mRNA and broader RNA therapeutics markets is underpinned by a confluence of scientific, strategic, and structural factors that continue to reinforce the value proposition of RNA as a therapeutic modality. Chief among these is the versatility of mRNA platforms, which enable rapid iteration and adaptation across diverse disease targets. Unlike traditional biologics, mRNA therapies can be designed and synthesized quickly once a target protein is identified, significantly reducing development timelines and enhancing responsiveness to emerging medical needs.
7.5.2 Another critical driver is the expansion of indications beyond infectious disease. While mRNA vaccine development initially gained traction through pandemic response, the pipeline has diversified to include oncology, autoimmune and inflammatory diseases, and a growing array of rare genetic disorders. The ability to elicit targeted immune responses or encode intracellular proteins that are otherwise difficult to deliver with conventional therapies has positioned mRNA as a compelling platform in these areas.[7][92]
7.5.3 Continued advances in delivery systems — especially LNP technologies — have further improved the pharmacokinetics, biodistribution, and tolerability of mRNA-based products. CDMOs and biopharma developers alike are also exploring next-generation delivery vectors tailored for tissue-specific targeting, which could broaden the range of treatable conditions and reduce off-target effects.
7.5.4 Investment activity from both the public and private sectors remains strong. Governments are funding RNA infrastructure as part of pandemic preparedness and biodefense strategies, while venture capital and strategic partnerships continue to flow into RNA-focused start-ups and platform developers. These investments are helping to build the long-term capacity and expertise needed to support large-scale production and regulatory advancement.
7.5.5 Finally, the expansion of the RNA modality pipeline is opening new therapeutic frontiers. Emerging technologies offer potential advantages in terms of potency, duration of expression, and precision of genetic modulation.[8][98] As these next-generation modalities move from proof-of-concept into clinical development, they are expected to contribute meaningfully to the pipeline volume, intellectual property landscape, and commercial opportunity of the broader RNA sector.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.